$Pyxis Oncology (PYXS.US)$ Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 Thursday, 19th December at 4:08 pm - The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors - Current cash runway expected to fund devel...
Its Friday with shorter trading time. Sleepy already. Some will run and some will get delayed market reaction. $Applied Therapeutics (APLT.US)$Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16% $PainReform (PRFX.US)$Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️ $Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$Merger ...
$Pyxis Oncology (PYXS.US)$ This is the PYXS entire press release from its website pyxisoncology.c... Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data PDF Version — PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo ther...
$Pyxis Oncology (PYXS.US)$ just posting this because it hasn't been talked about yet but the reason it's down is someone died during their trial. Most likely due to late stage cancer not because of the drug. Not a doctor. No position. Should bounce back though if this is the case imo. Good luck all!
Pyxis Oncology Stock Forum
Major Clinical Advance: Pyxis Teams with Merck for Groundbreaking Cancer Therapy Trial
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
Thursday, 19th December at 4:08 pm
- The Company will focus resources on advancing its lead asset, PYX-201
- PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors
- Current cash runway expected to fund devel...
📊⚡️📊
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$ Merger ...
This is the PYXS entire press release from its website
pyxisoncology.c...
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
PDF Version
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo ther...
No comment yet